Walleye Capital’s Puma Biotechnology PBYI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-13,055
Closed -$38.6K 4911
2025
Q1
$38.6K Sell
13,055
-25,790
-66% -$80.7K ﹤0.01% 3908
2024
Q4
$118K Buy
+38,845
New +$113K ﹤0.01% 4056
2023
Q2
Sell
-19,837
Closed -$61.3K 4757
2023
Q1
$61.3K Sell
19,837
-29,355
-60% -$111K ﹤0.01% 3136
2022
Q4
$208K Buy
49,192
+30,909
+169% +$107K ﹤0.01% 2022
2022
Q3
$43K Sell
18,283
-85,940
-82% -$251K ﹤0.01% 2618
2022
Q2
$297K Sell
104,223
-114,694
-52% -$285K 0.01% 1323
2022
Q1
$630K Sell
218,917
-184,202
-46% -$476K 0.02% 899
2021
Q4
$1.23M Buy
+403,119
New +$1.75M 0.04% 484
2020
Q1
Sell
-27,800
Closed -$244K 1469
2019
Q4
$244K Buy
+27,800
New +$230K 0.02% 1025
2019
Q3
Sell
-2,800
Closed -$36K 2168
2019
Q2
$36K Buy
+2,800
New +$64.5K ﹤0.01% 1438
2018
Q3
$124K Buy
+2,706
New +$130K 0.06% 248

Other funds holding PBYI

Walleye Capital's PBYI Position: Q2 2025 in Review

Walleye Capital sold out of Puma Biotechnology (PBYI) in Q2 2025, closing a stake of 13,055 shares — an estimated $38.6K sold.

Walleye Capital first reported a position in PBYI in Q3 2018 and held it in 11 quarters. The position peaked at $1.23M in Q4 2021. 121 funds tracked by Wall St. Rank hold PBYI as of Q2 2025.

  • Walleye Capital reported no remaining Puma Biotechnology position as of Q2 2025 after selling out during the quarter.
  • Walleye Capital sold 13,055 Puma Biotechnology shares in Q2 2025, an estimated $38.6K.
  • Walleye Capital first reported a position in Puma Biotechnology in Q3 2018 and held it in 11 quarters.
  • Walleye Capital's Puma Biotechnology position peaked at $1.23M in Q4 2021.
  • 121 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2025.

Based on Walleye Capital's 13F filing for Q2 2025, filed 13 Aug 2025.